Article Details

Roche's faricimab hits primary endpoint in wet AMD studies

Retrieved on: 2021-01-26 09:45:00

Tags for this article:

Click the tags to see associated articles and topics

Roche's faricimab hits primary endpoint in wet AMD studies. View article details on hiswai:

Excerpt

Roche's investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet ...

Article found on: www.pharmatimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up